GlassScriptPhysician profile
William M Carter
NPI 1720013873
$1,313.98
in general payments reported to CMS, 2019-2025
20 companies · $241 in 2025
The $241 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2020: $115 · 2021: $251 · 2022: $209 · 2023: $177 · 2024: $204 · 2025: $241.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $621.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $621.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $355.10 | 2021-2025 | Vraylar |
| Ironwood Pharmaceuticals, INC | $133.85 | 2019-2024 | Linzess |
| Glaxosmithkline, LLC. | $125.77 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $98.29 | 2020-2024 | Rybelsus |
| Novartis Pharmaceuticals Corporation | $88.92 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $85.62 | 2021-2024 | Breztri, Airsupra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $70.32 | 2019-2021 | |
| Amgen INC. | $54.22 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $46.99 | 2020-2022 | |
| Sk Life Science, INC. | $32.53 | 2021-2022 | |
| Lilly USA, LLC | $32.20 | 2022-2024 | Mounjaro, Zepbound |
| Axsome Therapeutics, INC. | $29.69 | 2024-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $28.71 | 2024 | Caplyta |
| Idorsia Pharmaceuticals US INC | $27.24 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $26.91 | 2021-2025 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $21.41 | 2025 | Korlym |
| Shield Therapeutics INC | $18.43 | 2023 | Accrufer |
| Astellas Pharma US INC | $14.05 | 2023 | Veozah |
| Genentech USA, INC. | $12.10 | 2021 | |
| Dexcom, INC. | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Carter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.